PRECIGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 USD | +0.71% |
|
+6.02% | +5.22% |
| Apr. 24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
| Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 891.5 | 1,892 | 767 | 316.4 | 333.6 | 351 | - | - |
| Enterprise Value (EV) 1 | 1,044 | 1,963 | 835 | 260.3 | 333.6 | 105 | 194 | 351 |
| P/E ratio | -2.62 x | -10 x | -7.89 x | 10.9 x | -3.44 x | -4.19 x | -6.17 x | 4.78 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.83 x | 18.3 x | 7.38 x | 11.8 x | 53.6 x | 62.8 x | 7.72 x | 1.26 x |
| EV / Revenue | 11.5 x | 19 x | 8.04 x | 9.67 x | 53.6 x | 18.8 x | 4.27 x | 1.26 x |
| EV / EBITDA | -7,027,991 x | - | - | - | - | - | - | - |
| EV / FCF | -6 x | -23.2 x | -13.3 x | -1.16 x | - | -1.46 x | -2.16 x | -3.62 x |
| FCF Yield | -16.7% | -4.31% | -7.55% | -86.3% | - | -68.6% | -46.4% | -27.6% |
| Price to Book | 12.5 x | 25.4 x | 7.15 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 162,683 | 185,463 | 206,738 | 208,150 | 248,919 | 248,919 | - | - |
| Reference price 2 | 5.480 | 10.20 | 3.710 | 1.520 | 1.340 | 1.410 | 1.410 | 1.410 |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/6/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.72 | 103.2 | 103.9 | 26.91 | 6.225 | 5.585 | 45.44 | 278.8 |
| EBITDA | -148.5 | - | - | - | - | - | - | - |
| EBIT 1 | -173.4 | -85.68 | -78.78 | -75.73 | -99.76 | -90.87 | -74.61 | 97.26 |
| Operating Margin | -191.14% | -83.04% | -75.84% | -281.42% | -1,602.54% | -1,626.96% | -164.21% | 34.89% |
| Earnings before Tax (EBT) 1 | -208.7 | -103.9 | -96.92 | -79.97 | -96.36 | -89.92 | -73.69 | 97.36 |
| Net income 1 | -322.3 | -170.5 | -92.17 | 28.32 | -95.9 | -89.55 | -73.69 | 80.21 |
| Net margin | -355.29% | -165.27% | -88.73% | 105.23% | -1,540.63% | -1,603.46% | -162.18% | 28.77% |
| EPS 2 | -2.090 | -1.020 | -0.4700 | 0.1400 | -0.3900 | -0.3363 | -0.2287 | 0.2950 |
| Free Cash Flow 1 | -173.8 | -84.55 | -63.02 | -224.7 | - | -72 | -90 | -97 |
| FCF margin | -191.59% | -81.94% | -60.67% | -834.94% | - | -1,289.16% | -198.08% | -34.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/6/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 21.56 | 24.22 | 32.02 | 2.911 | 16.72 | 1.763 | 1.851 | 1.767 | 1.379 | 1.228 | 1.48 | 1.48 | 1.48 | 1.48 | 16.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -25.47 | -20.49 | -17.41 | -24.16 | -7.614 | -21.8 | -23.48 | -21.12 | -20.94 | -34.22 | -22.38 | -22.62 | -22.93 | -23.24 | - |
| Operating Margin | -118.13% | -84.58% | -54.38% | -830.02% | -45.53% | -1,236.36% | -1,268.4% | -1,195.25% | -1,518.27% | -2,786.97% | -1,512.26% | -1,528.63% | -1,549.51% | -1,570.42% | - |
| Earnings before Tax (EBT) 1 | -29.88 | -25.02 | -19.31 | -26.15 | -7.694 | -22.17 | -22.79 | -20.38 | -19.8 | -33.39 | -22.11 | -22.35 | -22.66 | -22.97 | - |
| Net income 1 | -29.76 | -25.03 | -19.25 | -17.64 | 87.38 | -22.18 | -22.73 | -20.32 | -19.8 | -33.06 | -22.11 | -22.35 | -22.66 | -22.97 | - |
| Net margin | -138.05% | -103.36% | -60.12% | -605.81% | 522.54% | -1,257.86% | -1,228.2% | -1,149.92% | -1,435.46% | -2,691.86% | -1,493.68% | -1,510.05% | -1,530.93% | -1,551.84% | - |
| EPS 2 | -0.1500 | -0.1300 | -0.1000 | -0.0900 | 0.4400 | -0.1100 | -0.1000 | -0.0800 | -0.0800 | -0.1300 | -0.0880 | -0.0826 | -0.0845 | -0.0824 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/1/22 | 5/9/22 | 8/8/22 | 11/9/22 | 3/6/23 | 5/10/23 | 8/9/23 | 11/9/23 | 3/19/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 152 | 71.8 | 68 | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 56.1 | - | 246 | 157 | - |
| Leverage (Debt/EBITDA) | -1.025 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -174 | -84.5 | -63 | -225 | - | -72 | -90 | -97 |
| ROE (net income / shareholders' equity) | -80.8% | -246% | -106% | - | - | -103% | -107% | - |
| ROA (Net income/ Total Assets) | -29.9% | -44.3% | -27.3% | - | - | -49.9% | -54.7% | - |
| Assets 1 | 1,076 | 385.2 | 337.2 | - | - | 179.5 | 134.7 | - |
| Book Value Per Share | 0.4400 | 0.4000 | 0.5200 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 7.53 | 7.25 | 4.92 | - | 2.4 | 7 | 20 |
| Capex / Sales | - | 7.3% | 6.98% | 18.3% | - | 42.97% | 15.41% | 7.17% |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/6/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.41
USD
Average target price
9
USD
Spread / Average Target
+538.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.22% | 351M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PGEN Stock
- Financials Precigen, Inc.
